(Q40495167)

English

Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

3

object named as

Till Bongertz

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Andreas R Günthert

1

object named as

Andreas R Günthert

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Carsten Gründker

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Attila Nagy

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Günter Emons

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 October 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

87

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

255-264

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Anthracycline antibiotics in cancer therapy. Focus on drug resistance

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Gonadotropin-Releasing Hormone (GnRH)-Binding Sites in Human Breast Cancer Cell Lines and Inhibitory Effects of GnRH Antagonists*

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1007/S10549-004-8806-8

Identifiers

10.1007/S10549-004-8806-8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40495167&oldid=2203736554"